RDPAC药品推广行为准则 - IFPMA

法向具有相应处方权的医疗卫生专
业人士提供限量的样品,以更好地
服务于病患。所有样品均应被清楚
标注,以防止其被转卖或以其他方
式被滥用。
8.2 有效控制和责任落实
会员公司应对提供给医疗卫生
专业人士的样品建立有效的控制和
责任机制,包括对已交付给医药代
表的样品实施监控。
第九条 临床研究和透明度
9.1 透明度
会员公司致力于提高由其参与
支持的临床试验的透明度,并意识
到使执业医师、患者和其他人可从
公开渠道获得临床试验信息符合公
共健康的最大利益。而对此类信息
的公布又必须严格保护个人隐私、
知识产权、契约利益,并遵守现行
专利法的立法、行政及司法理论与
实践。
会员公司应依照由国际制药
企业协会联盟、欧洲制药企业协
maceutical product may be supplied
to healthcare professionals authorized
to prescribe that product at limited
amount for the purpose of familiarization
of healthcare professionals
with a product, in order to enhance
patient care. Samples should be
marked as such so that they cannot
be resold or otherwise misused.
8.2 Control and Accountability
Companies should have adequate
systems of control and accountability
for samples provided to healthcare
professionals including how to
look after such samples whilst they
are in possession of medical representatives.
Article 9 Clinical Research
and Transparency
9.1 Transparency
Companies are committed to the
transparency of clinical trials which
they sponsor. It is recognized that
there are important public health
benefits associated with making
clinical trial information more publicly
available to healthcare practitioners,
patients, and others. Such disclosure,
however, must maintain protections
for individual privacy, intellectual
property and contract rights, as well
as conform to legislation and current
national practices in patent law.
29
研
制
开
发
制
药
企
业
协
会